Memorial Sloan Kettering Cancer Center
New York, New York, United States
As a physician-scientist, I am focused on the development of novel biomarkers to better understand the pathogenesis of renal cell carcinoma (RCC) as well as the mechanisms of response and resistance to immune checkpoint inhibitors. I completed my MD/PhD at University of Michigan on the Medical Scientist Training Program (MSTP) with a PhD in Biologic Chemistry and a certificate in Biotechnology, where I investigated cross talk between the mTOR and p53 signal transduction pathways. I then completed my Internal Medicine Training at NYP - Cornell and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center as part of the ABIM Research Track, where I studied the metabolomics and the metabolic drivers of kidney cancer pathogeneis.
I am currently an Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, where I have lead multiple international clinical trials investigating novel combinations for both clear cell and non-clear cell renal cell carcinoma. I have also recieved external funding from Department of Defense for translational work investigating novel biomarkers for RCC.
Disclosure information not submitted.